New immunotherapy trial targets Hard-to-Treat advanced cancers

NCT ID NCT03736889

Recruiting now Disease control Sponsor: BeiGene Source: ClinicalTrials.gov ↗

Summary

This study is testing an immunotherapy drug called tislelizumab for people with advanced solid tumors that have specific genetic features (MSI-H or dMMR). The trial is for patients whose cancer has continued to grow despite previous treatments. Researchers want to see if this drug can help shrink tumors and control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Affiliated Hospital of Hebei University
RECRUITING

Baoding, Hebei, 071000, China
Affiliated Zhongshan Hospital of Fudan University
RECRUITING

Shanghai, Shanghai Municipality, 200032, China
Anhui Provincial Hospital
RECRUITING

Hefei, Anhui, 230000, China
Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, 100142, China
Cancer Hospital Chinese Academy of Medical Sciences
COMPLETED

Beijing, Beijing Municipality, 100021, China
Chongqing Cancer Hospital
RECRUITING

Chongqing, Chongqing Municipality, 400030, China
Fudan University Shanghai Cancer Center
COMPLETED

Shanghai, Shanghai Municipality, 200000, China
Fujian Medical University Union Hospital
RECRUITING

Fuzhou, Fujian, 350001, China
Guangdong Provincial Peoples Hospital
COMPLETED

Guangzhou, Guangdong, 510080, China
Harbin Medical University Cancer Hospital
RECRUITING

Harbin, Heilongjiang, 150000, China
Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, 450000, China
Hubei Cancer Hospital
COMPLETED

Wuhan, Hubei, 430079, China
Huizhou First Hospital
RECRUITING

Huizhou, Guangdong, 516000, China
Hunan Cancer Hospital
COMPLETED

Changsha, Hunan, 410013, China
Jiangsu Province Hospital
COMPLETED

Nanjing, Jiangsu, 210029, China
Jilin Cancer Hospital
RECRUITING

Changchun, Jilin, 130021, China
Meizhou People Hospital
RECRUITING

Meizhou, Guangdong, 514031, China
Nanfang Hospital of Southern Medical University
COMPLETED

Guangzhou, Guangdong, 510515, China
Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School
COMPLETED

Nanjing, Jiangsu, 210008, China
The Affiliated Hospital of Military Medical Sciences
COMPLETED

Beijing, Beijing Municipality, 100071, China
The First Affiliated Hospital, Zhejiang University School of Medicine
COMPLETED

Hangzhou, Zhejiang, 310003, China
The First Peoples Hospital of Yibin
RECRUITING

Yibin, Sichuan, 644000, China
The General Hospital of Shenyang Military
COMPLETED

Shenyang, Liaoning, 110016, China
The Peoples Hospital of Hechi
RECRUITING

Hechi, Guangxi, 547099, China
The Sixth Affiliated Hospital, Sun Yat Sen University
COMPLETED

Guangzhou, Guangdong, 510655, China
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
COMPLETED

Wuhan, Hubei, 430030, China
Yidu Central Hospital of Weifang
RECRUITING

Weifang, Shandong, 262550, China
Zhejiang Cancer Hospital
COMPLETED

Hangzhou, Zhejiang, 310022, China
Zhejiang University College of Medicine Second Affiliated Hospital
COMPLETED

Hangzhou, Zhejiang, 310009, China

Conditions

Explore the condition pages connected to this study.

MSI-H/DMMR SOLID TUMORS